Shamael R. Dastagir

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Antigen-specific immunotherapy of type 1 diabetes, typically via delivery of a single native β cell antigen, has had little clinical benefit to date. With increasing evidence that diabetogenic T cells react against multiple β cell antigens, including previously unappreciated neo-antigens that can be emulated by mimotopes, a shift from protein- to(More)
  • 1